Enmetazobactam

Enmetazobactam
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;
CAS Number	1001404-83-6;
PubChem CID	23653540;
DrugBank	DB18716;
ChemSpider	68025157;
UNII	80VUN7L00C;
KEGG	D12817;
ChEMBL	ChEMBL4458276;
Chemical and physical data
Formula	C11H14N4O5S
Molar mass	314.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C;
	InChI InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1; Key:HFZITXBUTWITPT-YWVKMMECSA-N;

Enmetazobactam (AAI-101) is an antibiotic adjuvant drug which acts as a beta-lactamase inhibitor, preventing the breakdown of other antibiotic drugs.^[1] Enmetazobactam was invented by a team of scientists at Orchid Pharma in India and then out-licensed to Allecra Therapeutics for further development.^[2] In the United States and European Union, enmetazobactam is approved for use in the combination cefepime/enmetazobactam (Exblifep).^[3]^[4]

References

^ Lanier C, Melton T, Covert K (September 2024). "Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor". The Annals of Pharmacotherapy. 59 (6): 570–576. doi:10.1177/10600280241279904. PMID 39329253.
^ US patent No.7687488B2 Novel 2-substituted methyl penam derivatives, https://worldwide.espacenet.com/patent/search/family/038949982/publication/US7687488B2?q=pn%3DUS7687488 Archived 5 April 2024 at the Wayback Machine
^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
^ "Exblifep EPAR". European Medicines Agency (EMA). 25 January 2024. Archived from the original on 4 February 2024. Retrieved 3 February 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[pmid39329253-1] Lanier C, Melton T, Covert K (September 2024). "Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor". The Annals of Pharmacotherapy. 59 (6): 570–576. doi:10.1177/10600280241279904. PMID 39329253.

[2] US patent No.7687488B2 Novel 2-substituted methyl penam derivatives, https://worldwide.espacenet.com/patent/search/family/038949982/publication/US7687488B2?q=pn%3DUS7687488 Archived 5 April 2024 at the Wayback Machine

[3] New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.

[4] "Exblifep EPAR". European Medicines Agency (EMA). 25 January 2024. Archived from the original on 4 February 2024. Retrieved 3 February 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]

[3]

[4]